GN Corporation's Academic Event NCRM NICHE Commemorates 21St Anniversary Of NCRM.

(MENAFN- AETOSWire) KOFU, Japan--(BUSINESS WIRE )--The XXI edition of Fujio Cup Quiz (FCQ) in NCRM NICHE 2026, hosted by GN Corporation, Japan and Nichi-In centre for Regenerative Medicine (NCRM), was won by Sameer Kumar Reddy and Chava Aravind Kumar from Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India. Ganga Anand Desai and Amith Mathew from Sri Ramachandra Institute of Higher Education and Research, Chennai, India, came runners.

International regenerative medicine event, NCRM NICHE, hosted by GNCorp continuously for the past 21 years, in academic partnership with German Society of Stem Cell research (GSZ) and Training program in Regenerative Medicine (TPRM), University of Toronto, to our knowledge, has the world's one and only active knowledge-gaining (AKG) event, FCQ, alongside passive knowledge-gaining (PKG) plenary lecture s and interdisciplinary conclave (IDC), with following features:

Educational platform: P ropagated knowledge on regenerative medicine to 4,000 scholars representing 190 institutes from 23 countries worldwide in two decades since 2006. Innovation platform: Interdisciplinary interactions led to tech-transfer of BEES‐HAUS cell-therapy, approved in Japan under Act on Safety of Regenerative Medicine. Networking cactus: Brings together clinicians from all specialities and experts across all domains of science relevant to tissue-engineering and hybrid biomaterials. Proceedings of NCRM NICHE

NCRM NICHE initiated collaborations have helped GNCorp develop and propagate many healthcare care solutions:

Simplified, one-step cell therapy: BHES-HAUS for male urethral stricture yielding encouraging clinical outcomes. Technology transfer of Autologous Immune Enhancement Therapy (AIET), using NK cells and T-cells for cance, to Malaysia and Vietnam. ICE-TUBE cell therapy Reversal of ageing A safe disease-modifying adjuvant for Duchenne Muscular Dystrophy, granted Rare Pediatric Disease (RPD) and Orphan Drug Designations (ODD) by the US FDA. STARMING implant with nine-years of safety and efficacy in Parry Romberg syndrome.

GNCorp is open for collaborating with likeminded institutes to co-host, NCRM NICHE, FCQ and partner with JSRM.

View source version on businesswire:

Permalink

MENAFN04112026004146001356ID1111913342